Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2542553rdf:typepubmed:Citationlld:pubmed
pubmed-article:2542553lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C0038477lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C1289971lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C2917177lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:2542553lifeskim:mentionsumls-concept:C0064502lld:lifeskim
pubmed-article:2542553pubmed:issue6lld:pubmed
pubmed-article:2542553pubmed:dateCreated1989-7-11lld:pubmed
pubmed-article:2542553pubmed:abstractTextThe synthesis of a series of 2-(phenylmethyl)-4-hydroxy-3,5-dialkylbenzofurans and their inhibitory effects against leukotriene biosynthesis and 5-lipoxygenase activity in vitro are described. Many compounds in this series were found to be potent inhibitors of LTB4 production by human polymorphonuclear leukocytes with IC50 values ranging from 7 to 100 nM. Structure-activity relationships of the series are presented. Within this series, 2-[(4'-methoxyphenyl)methyl]-4-hydroxy-3-methyl-5-propyl-7-chlorobenz ofuran (L-656,224) showed extremely potent activity, inhibiting leukotriene biosynthesis in intact human leukocytes (IC50 = 11 nM), as well as the 5-lipoxygenase reaction catalyzed by cell-free preparations from rat leukocytes (IC50 = 36 nM), human leukocytes (IC50 = 0.4 microM), and the purified enzyme from porcine leukocytes (IC50 = 0.4 microM). The compound also shows oral activity in a number of animal models in vivo.lld:pubmed
pubmed-article:2542553pubmed:languageenglld:pubmed
pubmed-article:2542553pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:citationSubsetIMlld:pubmed
pubmed-article:2542553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542553pubmed:statusMEDLINElld:pubmed
pubmed-article:2542553pubmed:monthJunlld:pubmed
pubmed-article:2542553pubmed:issn0022-2623lld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:MaycockA LALlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:BackWWlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:LauC KCKlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:DufresneCClld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:WilliamsH WHWlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:ScheigetzJJlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:DenisDDlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:BélangerP CPClld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:GuindonYYlld:pubmed
pubmed-article:2542553pubmed:authorpubmed-author:DallobA LALlld:pubmed
pubmed-article:2542553pubmed:issnTypePrintlld:pubmed
pubmed-article:2542553pubmed:volume32lld:pubmed
pubmed-article:2542553pubmed:ownerNLMlld:pubmed
pubmed-article:2542553pubmed:authorsCompleteNlld:pubmed
pubmed-article:2542553pubmed:pagination1190-7lld:pubmed
pubmed-article:2542553pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:meshHeadingpubmed-meshheading:2542553-...lld:pubmed
pubmed-article:2542553pubmed:year1989lld:pubmed
pubmed-article:2542553pubmed:articleTitleSynthesis and structure-activity relationships of a novel class of 5-lipoxygenase inhibitors. 2-(Phenylmethyl)-4-hydroxy-3,5-dialkylbenzofurans: the development of L-656,224.lld:pubmed
pubmed-article:2542553pubmed:affiliationDepartment of Medicinal Chemistry, Merck Frosst Canada Inc., Pointe Claire-Dorval, Québec, Canada.lld:pubmed
pubmed-article:2542553pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2542553pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2542553lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2542553lld:pubmed